Solid Malignancies Clinical Trial
Official title:
Pharmacodynamic Study Using FLT-PET/CT in Patients With Prostate and Other Solid Malignancies Treated With an Interrupted High-dose Axitinib Schedule
Verified date | December 2014 |
Source | University of Wisconsin, Madison |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main purpose of this study is to learn more about the safety of an investigational drug,
axitinib. An investigational drug is a drug that has not been approved by the Food and Drug
Administration (FDA) and is available for research use only. Researchers will also see what
changes happen to the tumors while taking the axitinib and after it is stopped (during the
scheduled breaks), and what changes in the tumor may be responsible for this growth. This
will be done by using a special kind of scan called an 18F-FLT PET/CT. This scan is
considered an investigational type of scan and is not used for clinical care. These scans are
not approved by the FDA, their use in this study is just for research purposes.
In addition, the investigators want to find out how the drug is processed and distributed in
the human body. The investigators will also look at how different types of cancer are
affected by axitinib.
Status | Completed |
Enrollment | 24 |
Est. completion date | December 2014 |
Est. primary completion date | September 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients must have histologically or cytologically confirmed solid malignancy (excluding lymphoma) that is metastatic or unresectable and for which no standard therapy exists. - Patients must have measurable disease - Must be >/= 18 years of age - All patients need to be willing to undergo planned pharmacodynamic assessments, including serial PET imaging, plasma markers, and pharmacokinetic sampling. Exclusion Criteria: - Patients who have had chemotherapy, radiotherapy, experimental therapy or major surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered (to grade -Patients may not be receiving any other investigational agents. - Patients with prior anti-VEGF directed therapy may be allowed only if approved by the PI and greater than 8 weeks since last exposure - History of allergic reactions attributed to compounds of similar chemical or biologic composition to axitinib - Patients with poorly controlled hypertension - Patients who require use of therapeutic doses of coumarin-derivative anticoagulants - Patients with any condition that impairs their ability to swallow and retain axitinib tablets are excluded. - Patients with any of the following conditions are excluded: Serious or nonhealing wound, ulcer, or bone fracture; History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of treatment; Any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study entry; History of myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within 12 months prior to study entry; History of pulmonary embolism within the past 12 months; Class III or IV heart failure as defined by the NYHA functional classification system. - Patients without appropriate lesion on CT scan for FLT-PET/CT imaging - CYP3A4 inducers/inhibitors medications will be reviewed by the Principal Investigator. - Steroid use is not recommended during axitinib treatment - Patients with a pre-existing thyroid abnormality who are unable to maintain thyroid function in the normal range with medication are ineligible. - Patients with known brain metastases should be excluded - HIV-positive patients on combination antiretroviral therapy are ineligible |
Country | Name | City | State |
---|---|---|---|
United States | University of Wisconsin Carbone Cancer Center | Madison | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison | Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pharmacodynamic change on FLT-PET/CT | baseline, cycle 1 weeks 2 and 3, pre-cycle 3, cycle 3 weeks 2 and 3 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01202370 -
A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies
|
Phase 1 | |
Completed |
NCT00162136 -
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
|
Phase 1 | |
Recruiting |
NCT05006794 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT02537418 -
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
|
Phase 1 | |
Completed |
NCT00033202 -
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor
|
Phase 1 | |
Recruiting |
NCT04492735 -
The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
|
||
Completed |
NCT05866354 -
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
|
Phase 1 | |
Completed |
NCT02640755 -
Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
|
Phase 1 | |
Terminated |
NCT00695370 -
Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children
|
Phase 2 | |
Completed |
NCT02325739 -
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
|
Phase 1/Phase 2 | |
Completed |
NCT00676299 -
A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.
|
Phase 1 | |
Active, not recruiting |
NCT00090727 -
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
|
Phase 1 | |
Terminated |
NCT01112397 -
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
|
Phase 1 | |
Not yet recruiting |
NCT00751894 -
Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)
|
Phase 2 |